Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    Open Studies | "Inflammatory Breast Neoplasms"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Inflammatory Breast Neoplasms" (26 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Inflammatory Breast Carcinoma;   Stage IV Breast Cancer;   Stage IV Inflammatory Breast Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
2 Recruiting Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
Intervention:
3 Recruiting Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
4 Recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
5 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
6 Recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
7 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
8 Recruiting Inflammatory Breast Cancer (IBC) Registry
Condition: Breast Cancer
Interventions: Other: Interview;   Procedure: Blood and Tissue Collection
9 Unknown  Dose-escalation Study of Oral CX-4945
Conditions: Advanced Solid Tumors;   Breast Cancer;   Inflammatory Breast Cancer;   Castleman's Disease;   Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
10 Not yet recruiting A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up
11 Recruiting MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: MK-3475;   Behavioral: Follow Up/Phone Call
12 Recruiting Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: BIBF 1120;   Behavioral: Phone Call
13 Recruiting MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer
Condition: Breast Cancer
Intervention:
14 Recruiting Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy
Conditions: Invasive Ductal Breast Cancer;   Tubular Breast Cancer;   Mucinous Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil
15 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
16 Recruiting Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Conditions: Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gonadotropin-releasing hormone agonist;   Drug: Letrozole
17 Recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
18 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage IIA Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer;   Stage IIB Breast Cancer;   Estrogen Receptor Negative;   Progesterone Receptor Negative;   HER2/Neu Negative
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
19 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Breast Adenocarcinoma;   Inflammatory Breast Carcinoma
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
20 Unknown  "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
Conditions: Infiltrating Duct and Lobular Carcinoma In Situ;   Invasive Lobular Breast Carcinoma;   Inflammatory Breast Carcinoma
Intervention: Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years